Ali Tavakoli Pirzaman

Dr. Ali Tavakoli Pirzaman

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in Human & Experimental Toxicology
Verified
Journal Article
Open access
APAli Tavakoli Pirzaman
Ali Tavakoli Pirzaman
PEPouyan Ebrahimi
Pouyan Ebrahimi
SNShokat Niknezhad
Shokat Niknezhad
TVTuran Vahidi
Turan Vahidi
DHDariush Hosseinzadeh
Dariush Hosseinzadeh
SKSohrab Kazemi
Sohrab Kazemi
Incidence and mortality rates of gastrointestinal (GI) and oral cancers are among the highest in the world, compared to other cancers. GI cancers include esophageal, gastric, colon, rectal, liver, and pancreatic cancers, with colorectal cancer being the most common. Oral cancer, which is included in the head and neck cancers category, is one of the most important causes of death in India. Cadmium (Cd) is a toxic element affecting humans and the environment, which has both natural and anthropogenic sources. Generally, water, soil, air, and food supplies are reported as some sources of Cd. It accumulates in organs, particularly in the kidneys and liver. Exposure to cadmium is associated with different types of health risks such as kidney dysfunction, cardiovascular disease, reproductive dysfunction, diabetes, cerebral infarction, and neurotoxic effects (Parkinson’s disease (PD) and Alzheimer’s disease (AD)). Exposure to Cd is also associated with various cancers, including lung, kidney, liver, stomach, hematopoietic system, gynecologic and breast cancer. In the present study, we have provided and summarized the association of Cd exposure with oral and GI cancers.

4 October 2024 in eClinicalMedicine
Verified
Journal Article
Open access
APAli Tavakoli Pirzaman
Ali Tavakoli Pirzaman
MSMahdi Sepidarkish
Mahdi Sepidarkish
FAFaezeh Alizadeh
Faezeh Alizadeh
SASarah Al-Obidy
Sarah Al-Obidy
PEPouyan Ebrahimi
Pouyan Ebrahimi
ARAli Rostami
Ali Rostami
Schistosoma mansoni infection poses a substantial public health challenge globally, and the World Health Organization (WHO) aims for the elimination of schistosomiasis by 2030. This study aimed to assess the current prevalence of human S. mansoni infection in endemic regions worldwide between 2010 and 2024. We conducted a comprehensive search in PubMed/Medline and Scopus databases as well as other public sources from 1 January 2010 to 15 July 2024. Population-based studies reporting the prevalence of S. mansoni infection were eligible. We undertook a random-effects meta-analysis to estimate pooled prevalences with 95% confidence intervals (CIs) in WHO-defined regions and assessed potential risk factors associated with S. mansoni infection. The protocol for this study was registered on PROSPERO (CRD42023438455). We identified a total of 542 eligible studies involving 1,163,866 individuals who had been tested for S. mansoni infection in 38 countries. The overall, pooled global prevalence of S. mansoni infection in endemic region was 14.8% (95% CI, 13.5%–16.1%). The pooled prevalences (95% CI) in specific regions were: 15.3% (13.9–16.8%) in sub-Saharan Africa, 12.4% (8.9–16.4%) in South America and 9.5% (5.4–14.6%) in the Eastern Mediterranean region. There was a 52.6% decrease in prevalence of S. mansoni infection and a 37% decrease in high-intensity infection for studies conducted between 2010 and 2014 compared to those conducted between 2020 and 2023. The present analysis revealed that factors including male gender, bathing or swimming in natural water bodies, crossing rivers or lakes, and engaging in water irrigation activities such as fishing, working in rice paddies or maintaining irrigation canals were significantly associated with S. mansoni infection. The findings of this investigation revealed that, despite a decline in prevalence and high-intensity infection, 7–12% of people in endemic regions, notably in sub-Saharan Africa, remained affected by schistosomiasis mansoni between 2020 and 2024. This study provides data of relevance to policymakers to support efforts to eliminate this disease. This study received no funding.

27 May 2022 in Reviews in Medical Virology
Verified
Journal Article
Closed access
ZAZeinab Mohseni Afshar
Zeinab Mohseni Afshar
MBMohammad Barary
Mohammad Barary
ABArefeh Babazadeh
Arefeh Babazadeh
APAli Tavakoli Pirzaman
Ali Tavakoli Pirzaman
RHRezvan Hosseinzadeh
Rezvan Hosseinzadeh
Soheil EbrahimpourSoheil Ebrahimpour
Soheil Ebrahimpour

2 February 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
ZAZeinab Mohseni Afshar
Zeinab Mohseni Afshar
APAli Tavakoli Pirzaman
Ali Tavakoli Pirzaman
BKBardia Karim
Bardia Karim
SAShiva Rahimipour Anaraki
Shiva Rahimipour Anaraki
RHRezvan Hosseinzadeh
Rezvan Hosseinzadeh
Soheil EbrahimpourSoheil Ebrahimpour
Soheil Ebrahimpour
Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, there have been multiple peaks of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus virus 2) infection, mainly due to the emergence of new variants, each with a new set of mutations in the viral genome, which have led to changes in the pathogenicity, transmissibility, and morbidity. The Omicron variant is the most recent variant of concern (VOC) to emerge and was recognized by the World Health Organization (WHO) on 26 November 2021. The Omicron lineage is phylogenetically distinct from earlier variants, including the previously dominant Delta SARS-CoV-2 variant. The reverse transcription–polymerase chain reaction (RT–PCR) test, rapid antigen assays, and chest computed tomography (CT) scans can help diagnose the Omicron variant. Furthermore, many agents are expected to have therapeutic benefits for those infected with the Omicron variant, including TriSb92, molnupiravir, nirmatrelvir, and their combination, corticosteroids, and interleukin-6 (IL-6) receptor blockers. Despite being milder than previous variants, the Omicron variant threatens many lives, particularly among the unvaccinated, due to its higher transmissibility, pathogenicity, and infectivity. Mounting evidence has reported the most common clinical manifestations of the Omicron variant to be fever, runny nose, sore throat, severe headache, and fatigue. This review summarizes the essential features of the Omicron variant, including its history, genome, transmissibility, clinical manifestations, diagnosis, management, and the effectiveness of existing vaccines against this VOC.

30 June 2023 in Clinical and Translational Science
Verified
Journal Article
Open access
ZAZeinab Mohseni Afshar
Zeinab Mohseni Afshar
APAli Tavakoli Pirzaman
Ali Tavakoli Pirzaman
RHRezvan Hosseinzadeh
Rezvan Hosseinzadeh
ABArefeh Babazadeh
Arefeh Babazadeh
MMMohamad Ali Taghizadeh Moghadam
Mohamad Ali Taghizadeh Moghadam
Soheil EbrahimpourSoheil Ebrahimpour
Soheil Ebrahimpour
Coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), can manifest itself in several ways, including coagulopathy and thrombosis. These complications can be the first and sometimes only manifestations of SARS‐CoV‐2 infection and can occur early or late in the course of the disease. However, these symptoms are more prevalent in hospitalized patients with venous thromboembolism, particularly those admitted to intensive care units. Moreover, various forms of arterial and venous thrombosis, or micro‐ or macro‐vasculature embolisms, have been reported during the current pandemic. They have led to harmful consequences, such as neurological and cardiac events, nearly all resulting from the hypercoagulable state caused by this viral infection. The severe hypercoagulability observed in patients with COVID‐19 accounts for most cases of the disease that become critical. Therefore, anticoagulants seem to be one of the most vital therapeutics for treating this potentially life‐threatening condition. In the current paper, we present a thorough review of the pathophysiology of COVID‐19‐induced hypercoagulable state and the use of anticoagulants to treat SARS‐CoV‐2 infections in different patient groups, as well as their pros and cons.

5 June 2022
Verified
Preprint
Open access
PDF file
ZAZeinab Mohseni Afshar
Zeinab Mohseni Afshar
HRHossein Nazari Rostami
Hossein Nazari Rostami
RHRezvan Hosseinzadeh
Rezvan Hosseinzadeh
AJAlireza Janbakhsh
Alireza Janbakhsh
APAli Tavakoli Pirzaman
Ali Tavakoli Pirzaman
Soheil EbrahimpourSoheil Ebrahimpour
Soheil Ebrahimpour
Human monkeypox is a zoonotic Orthopoxvirus resembling smallpox in clinical course, making it difficult to distinguish it from smallpox and varicella. Laboratory diagnostics are critical components of illness identification and surveillance, and novel tests are required for more precise and quick diagnosis. The majority of human infections occur in Central Africa, where monitoring in remote regions with little infrastructure is challenging but may be performed using evidence-based methods and teaching materials that educate public health personnel on the fundamental principles of this infection. New medications and vaccinations showed promising results for the treatment and prevention of the disease, but more studies are required to show their efficacy in the actual endemic settings. Thus, more studies are needed on the virus's epidemiology, ecology, and biology in endemic locations to better understand and prevent human infections. This review discussed the etiology, epidemiology, and clinical course of the monkeypox and indicated diagnostic and treatment approaches for this disease.